Clinical Trial Update: Activation of NOD2 Receptors in Preterm Infants by Lactobacillus Reuteri DSM17938 [NA]

View source ↗

Summary

A completed clinical trial assessed whether the probiotic Lactobacillus reuteri DSM17938 activates NOD2 receptors in preterm infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Lactobacillus reuteri DSM17938 (Lactobacillus reuteri DSM17938)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Preterm Infants | NA | Status: COMPLETED